Wordt geladen...
Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer
Based on demonstrated favourable risk–benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-small-cell lung cancer (nsclc) and nsclc subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Multimed Inc.
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4189574/ https://ncbi.nlm.nih.gov/pubmed/25302040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.21.1997 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|